A Phase 1, Open-Label, Multicenter Study of INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Latest Information Update: 12 Feb 2026
At a glance
- Drugs INCA 036873 (Primary)
- Indications B-cell lymphoma; Clear cell sarcoma; Cutaneous T-cell lymphoma; Diffuse large B cell lymphoma; Peripheral T-cell lymphoma; Renal cell carcinoma; Solid tumours
- Focus Adverse reactions
- Sponsors Incyte Corporation
Most Recent Events
- 23 Jan 2026 Status changed from not yet recruiting to recruiting.
- 08 Oct 2025 New trial record